

Docket No. 46963-DIV (1417)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Isner, J., et al.

Serial No.: 09/228,020



Examiner: F. VanderVegt

Filed: January 11, 1999

Group No.: 1644

For: METHODS FOR REGULATING ANGIOGENESIS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**STATEMENTS IN SUPPORT OF FILING
AND SUBMISSIONS IN ACCORDANCE WITH 37 CFR §§1.821-1.825**

In accordance with 37 CFR §§1.821-1.825, I hereby state that the content of the paper copy of the sequence listing submitted, i.e. substitute pages 42-43, in accordance with 37 CFR §1.821(c) and (e), respectively, are the same. I hereby state that the submission, filed in accordance with 37 CFR §1.821(g), does not introduce new matter.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "R.L.B." or "Robert L. Buchanan".

Robert L. Buchanan
Registration No. 40,927
EDWARDS & ANGELL, LLP
DIKE, BRONSTEIN, ROBERTS &
CUSHMAN
Intellectual Property Practice Group
130 Water St.
Boston, MA 02109-4280
Tel. (617) 523-3400

Date: December 7, 2000

#146219

B



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set by the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF-Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

RECEIVED

DEC 14 2007

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

TECH CENTER 1600/2900

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

B